{
    "organizations": [],
    "uuid": "21cc9c37ac696229df8de9355ff0e8af4f2f8552",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-esperion-announces-third-pivotal-p/brief-esperion-announces-third-pivotal-phase-3-study-of-bempedoic-acid-meets-primary-endpoint-idUSFWN1SU0SD",
    "ord_in_thread": 0,
    "title": "BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT\n* ESPERION - STUDY 3 ACHIEVES ADDITIONAL 26% LDL-C LOWERING ON BACKGROUND OF MAXIMALLY TOLERATED LDL-C LOWERING THERAPY IN PATIENTS CONSIDERED STATIN INTOLERANT\n* ESPERION THERAPEUTICS INC - CUMULATIVE PHASE 2 / PHASE 3 DEMONSTRATES BROAD EFFICACY AS WELL AS SAFETY AND TOLERABILITY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T21:27:00.000+03:00",
    "crawled": "2018-05-24T20:14:52.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "esperion",
        "therapeutic",
        "inc",
        "esperion",
        "announces",
        "third",
        "pivotal",
        "phase",
        "study",
        "bempedoic",
        "acid",
        "meet",
        "primary",
        "endpoint",
        "esperion",
        "study",
        "achieves",
        "additional",
        "lowering",
        "background",
        "maximally",
        "tolerated",
        "lowering",
        "therapy",
        "patient",
        "considered",
        "statin",
        "intolerant",
        "esperion",
        "therapeutic",
        "inc",
        "cumulative",
        "phase",
        "phase",
        "demonstrates",
        "broad",
        "efficacy",
        "well",
        "safety",
        "tolerability",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}